查找临床试验
已按「重症肌无力」检索，对应国际通用词 myasthenia gravis
共找到 31 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 23:03，每 5 分钟自动同步Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
China
年龄 18 Years – 不限
Candid Therapeutics
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
China
年龄 18 Years – 70 Years
Shanghai Jiaolian Drug Research and Development Co., Ltd
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
China
年龄 18 Years – 不限
Huashan Hospital
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
United States、Brazil、Japan、Poland、Taiwan
年龄 6 Years – 17 Years
Alexion Pharmaceuticals, Inc.
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
United States、Australia、Belgium、Canada、China 等 12 国
年龄 18 Years – 不限
Janssen Research & Development, LLC
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
China
年龄 18 Years – 70 Years
Tongji Hospital
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
China
年龄 18 Years – 75 Years
Guangdong Hengrui Pharmaceutical Co., Ltd
Biomarkers in Autoimmune Disease of Nervous System
China
年龄 18 Years – 不限
Tongji Hospital
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
United States、China、Japan、Spain
年龄 18 Years – 不限
UCB Biopharma SRL
Cohort Study on Neuroimmune Diseases in the Reproductive Age
China
年龄 20 Years – 55 Years
Third Affiliated Hospital, Sun Yat-Sen University
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
China
年龄 12 Years – 80 Years
RemeGen Co., Ltd.
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
China
年龄 18 Years – 60 Years
Tianjin Medical University General Hospital